InvestmentApr 13, 2026, 04:03 PM
Revolution Medicines to Offer $750M Stock & $250M Convertible Notes
AI Summary
Revolution Medicines announced its intention to raise capital through separate public offerings. The company plans to offer $750 million of common stock and $250 million in convertible senior notes due 2033. Underwriters will also have options to purchase additional common stock and notes. The net proceeds from both offerings are intended for general corporate purposes, including research and development, potential commercialization of product candidates, and general administrative expenses.
Key Highlights
- Revolution Medicines intends to offer $750 million of common stock.
- The company plans to offer $250 million aggregate principal amount of convertible senior notes due 2033.
- Underwriters have 30-day options for an additional $112.5 million in common stock and $37.5 million in notes.
- Proceeds will be used for general corporate purposes, including R&D and potential commercialization.